These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38696157)

  • 21. Prevalence of mild cognitive impairment subtypes in patients attending a memory outpatient clinic--comparison of two modes of mild cognitive impairment classification. Results of the Vienna Conversion to Dementia Study.
    Pusswald G; Moser D; Gleiss A; Janzek-Hawlat S; Auff E; Dal-Bianco P; Lehrner J
    Alzheimers Dement; 2013 Jul; 9(4):366-76. PubMed ID: 23164551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of nimodipine and choline alphoscerate in the treatment of cognitive impairment in patients with cerebral small vessel disease: study protocol for a randomized placebo-controlled trial-the CONIVaD trial.
    Salvadori E; Poggesi A; Donnini I; Rinnoci V; Chiti G; Squitieri M; Tudisco L; Fierini F; Melone A; Pescini F; Pantoni L
    Aging Clin Exp Res; 2020 Mar; 32(3):449-457. PubMed ID: 31148099
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of Chinese medicine for tonifying the kidney and resolving phlegm and blood stasis in treating patients with amnestic mild cognitive impairment: a randomized, double-blind and parallel-controlled trial.
    Miao YC; Tian JZ; Shi J; Mao M
    Zhong Xi Yi Jie He Xue Bao; 2012 Apr; 10(4):390-7. PubMed ID: 22500712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Altered microbiomes distinguish Alzheimer's disease from amnestic mild cognitive impairment and health in a Chinese cohort.
    Liu P; Wu L; Peng G; Han Y; Tang R; Ge J; Zhang L; Jia L; Yue S; Zhou K; Li L; Luo B; Wang B
    Brain Behav Immun; 2019 Aug; 80():633-643. PubMed ID: 31063846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amyloid-Independent Amnestic Mild Cognitive Impairment and Serum Apolipoprotein A1 Levels.
    Choi HJ; Seo EH; Yi D; Sohn BK; Choe YM; Byun MS; Lee JM; Woo JI; Lee DY
    Am J Geriatr Psychiatry; 2016 Feb; 24(2):144-53. PubMed ID: 26238231
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predicting progression of amnesic MCI: The integration of episodic memory impairment with perfusion SPECT.
    Quaranta D; Gainotti G; Di Giuda D; Vita MG; Cocciolillo F; Lacidogna G; Guglielmi V; Masullo C; Giordano A; Marra C
    Psychiatry Res Neuroimaging; 2018 Jan; 271():43-49. PubMed ID: 29129545
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuropsychiatric predictors of conversion to dementia both in patients with amnestic mild cognitive impairment and those with subcortical vascular MCI.
    Kim SH; Kang HS; Kim HJ; Ryu HJ; Kim My; Seo SW; Na DL; Han SH
    Clin Neurol Neurosurg; 2013 Aug; 115(8):1264-70. PubMed ID: 23290121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Delayed effects of cerebrolysin in the prevention of cognitive impairment progression in the first degree relatives of patients with Alzheimer's disease: the role of the ApoE genotype].
    Selezneva ND; Gavrilova SI; Kolykhalov IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(10. Vyp. 2):31-38. PubMed ID: 33205928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pre-MCI and MCI: neuropsychological, clinical, and imaging features and progression rates.
    Duara R; Loewenstein DA; Greig MT; Potter E; Barker W; Raj A; Schinka J; Borenstein A; Schoenberg M; Wu Y; Banko J; Potter H
    Am J Geriatr Psychiatry; 2011 Nov; 19(11):951-60. PubMed ID: 21422909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Depressive Symptoms on Conversion from Mild Cognitive Impairment Subtypes to Alzheimer's Disease: A Community-Based Longitudinal Study.
    Kida J; Nemoto K; Ikejima C; Bun S; Kakuma T; Mizukami K; Asada T
    J Alzheimers Dis; 2016; 51(2):405-15. PubMed ID: 26890740
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predicting outcome in mild cognitive impairment: 4-year follow-up study.
    Lonie JA; Parra-Rodriguez MA; Tierney KM; Herrmann LL; Donaghey C; O'Carroll RE; Ebmeier KP
    Br J Psychiatry; 2010 Aug; 197(2):135-40. PubMed ID: 20679266
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.
    Visser PJ; Verhey F; Knol DL; Scheltens P; Wahlund LO; Freund-Levi Y; Tsolaki M; Minthon L; Wallin AK; Hampel H; Bürger K; Pirttila T; Soininen H; Rikkert MO; Verbeek MM; Spiru L; Blennow K
    Lancet Neurol; 2009 Jul; 8(7):619-27. PubMed ID: 19523877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resting state functional connectivity abnormalities and delayed recall performance in patients with amnestic mild cognitive impairment.
    Joshi H; Bharath S; John JP; Sadanand S; Saini J; Kumar K; Varghese M
    Brain Imaging Behav; 2020 Feb; 14(1):267-277. PubMed ID: 30421086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The use of cerepro (choline alfoscerate) in the treatment of outpatients with chronic progressive cerebrovascular disease].
    Kostenko EV; Petrova LV; Artemova IIu; Vdovichenko TV; Ganzhula PA; Ismailov AM; Lisenker LN; Petrov SV; Otcheskaia OV; Rotor LD; Khozova AA; Boĭko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(3 Pt 1):24-30. PubMed ID: 22677751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blood biomarkers as surrogate endpoints of treatment responses to aerobic exercise and cognitive training (ACT) in amnestic mild cognitive impairment: the blood biomarkers study protocol of a randomized controlled trial (the ACT Trial).
    Li D; Mielke MM; Bell WR; Reilly C; Zhang L; Lin FV; Yu F
    Trials; 2020 Jan; 21(1):19. PubMed ID: 31907024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Safety of the Association of Nimodipine and Choline Alphoscerate in the Treatment of Cognitive Impairment in Patients with Cerebral Small Vessel Disease. The CONIVaD Trial.
    Salvadori E; Poggesi A; Donnini I; Rinnoci V; Chiti G; Squitieri M; Tudisco L; Fierini F; Melone A; Pescini F; Pantoni L
    Drugs Aging; 2021 Jun; 38(6):481-491. PubMed ID: 33855653
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abnormal inhibition of return in mild cognitive impairment: is it specific to the presence of prodromal dementia?
    Bayer A; Phillips M; Porter G; Leonards U; Bompas A; Tales A
    J Alzheimers Dis; 2014; 40(1):177-89. PubMed ID: 24366922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical relevance of amnestic versus non-amnestic mild cognitive impairment subtyping in Parkinson's disease.
    Chung SJ; Park YH; Yun HJ; Kwon H; Yoo HS; Sohn YH; Lee JM; Lee PH
    Eur J Neurol; 2019 May; 26(5):766-773. PubMed ID: 30565368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conversion and Reversion Rates in Japanese Older People With Mild Cognitive Impairment.
    Shimada H; Makizako H; Doi T; Lee S; Lee S
    J Am Med Dir Assoc; 2017 Sep; 18(9):808.e1-808.e6. PubMed ID: 28711424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Typicality of words produced on a semantic fluency task in amnesic mild cognitive impairment: linguistic analysis and risk of conversion to dementia.
    Vita MG; Marra C; Spinelli P; Caprara A; Scaricamazza E; Castelli D; Canulli S; Gainotti G; Quaranta D
    J Alzheimers Dis; 2014; 42(4):1171-8. PubMed ID: 25024315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.